Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
0.9400
-0.0049 (-0.52%)
At close: Mar 4, 2026, 4:00 PM EST
0.9399
-0.0001 (-0.01%)
After-hours: Mar 4, 2026, 7:43 PM EST
Biodexa Pharmaceuticals Employees
Biodexa Pharmaceuticals had 13 employees as of December 31, 2024. The number of employees decreased by 8 or -38.10% compared to the previous year.
Employees
13
Change (1Y)
-8
Growth (1Y)
-38.10%
Revenue / Employee
n/a
Profits / Employee
-$656,254
Market Cap
788.46K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 13 | -8 | -38.10% |
| Dec 31, 2023 | 21 | -6 | -22.22% |
| Dec 31, 2022 | 27 | 7 | 35.00% |
| Dec 31, 2021 | 20 | 2 | 11.11% |
| Dec 31, 2020 | 18 | -47 | -72.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyra Therapeutics | 30 |
| Aditxt | 26 |
| Virax Biolabs Group | 19 |
| Azitra | 12 |
| Ensysce Biosciences | 8 |
| CDT Equity | 6 |
| Onconetix | 5 |
| CNS Pharmaceuticals | 5 |
BDRX News
- 13 days ago - Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer - Accesswire
- 4 weeks ago - Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST - GlobeNewsWire
- 2 months ago - Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary - GlobeNewsWire
- 2 months ago - Biodexa Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 3 months ago - Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP - GlobeNewsWire
- 3 months ago - Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP - GlobeNewsWire
- 4 months ago - Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion - GlobeNewsWire
- 5 months ago - Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025 - GlobeNewsWire